GlassScriptPhysician profile
Daniel J Kmetz
NPI 1659766319
$10,142.85
in general payments reported to CMS, 2019-2025
39 companies · $1,982 in 2025
The $1,982 reported for 2025 was more than what 80% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $447 · 2020: $631 · 2021: $1,800 · 2022: $1,206 · 2023: $1,917 · 2024: $2,159 · 2025: $1,982.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,020 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $38.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,019.73 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $38.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,091.93 | 2021-2025 | Interstim, Altaviva |
| Axonics, INC. | $924.95 | 2021-2022 | |
| Teleflex LLC | $733.31 | 2021-2024 | Urolift |
| Boston Scientific Corporation | $718.76 | 2019-2025 | Ams 700, Lithovue, Spaceoar Vue System - 10ml |
| Procept Biorobotics Corporation | $527.34 | 2023-2025 | Aquabeam System, Aquabeam Robotic System |
| Sumitomo Pharma America, INC. | $427.35 | 2023-2025 | Gemtesa, Orgovyx |
| Endo Pharmaceuticals INC. | $369.93 | 2020-2024 | Xiaflex, Aveed, Edex |
| Endo USA, INC. | $355.48 | 2024-2025 | Xiaflex, Aveed |
| Genzyme Corporation | $325.00 | 2020 | |
| Myriad Genetic Laboratories, INC. | $232.86 | 2022-2024 | Prolaris |
| Halozyme INC | $222.87 | 2023 | |
| Abbvie INC. | $189.04 | 2023-2025 | |
| Urogen Pharma, INC. | $169.09 | 2022-2025 | Jelmyto |
| Astellas Pharma US INC | $147.40 | 2020 | |
| Medtronic USA, INC. | $144.42 | 2019-2020 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $143.54 | 2024 | 1788 |
| Urovant Sciences INC | $129.29 | 2021-2022 | |
| Sanara Medtech INC. | $127.27 | 2025 | Celleraterx |
| Accord Healthcare, INC. | $126.36 | 2025 | |
| Antares Pharma, INC. | $108.43 | 2021-2025 | Xyosted |
| Janssen Scientific Affairs, LLC | $105.92 | 2019 | |
| Calyxo, INC. | $97.93 | 2025 | Cvac Aspiration System |
| Biotissue Holdings INC. | $76.80 | 2019 | |
| Janssen Biotech, INC. | $70.60 | 2025 | |
| Neotract INC. | $70.22 | 2019-2020 | |
| Verity Pharmaceuticals INC. | $66.13 | 2024-2025 | Trelstar |
| Ferring Pharmaceuticals INC. | $54.87 | 2024 | Adstiladrin |
| Bioprotect Medical, INC. | $53.64 | 2024-2025 | Bioprotect Balloon Implant System |
| Olympus America INC. | $50.69 | 2025 | Itind System |
| Astrazeneca Pharmaceuticals LP | $44.77 | 2025 | Lynparza |
| Vertex Pharmaceuticals Incorporated | $41.48 | 2025 | |
| Coloplast Corp | $41.04 | 2021-2024 | |
| Siemens Medical Solutions USA, INC. | $38.88 | 2021 | |
| Pfizer INC. | $29.60 | 2024 | |
| Myovant Sciences INC. | $26.95 | 2022 | |
| Blue Earth Diagnostics | $25.51 | 2021 | |
| Amgen INC. | $20.59 | 2021 | |
| Baudax Bio INC. | $12.61 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$9,770.18 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Kmetz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.